Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics
Study context
- Population
- Adults ≥45 years with atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL despite maximally tolerated lipid-modifying therapyplanned
- Participants
- 300 adults
- Planned comparison
- Obicetrapib/ezetimibe fixed-dose combination (FDC) vs placebo
- Primary endpoint
- Percent change in total noncalcified coronary plaque volume (NCPV) by coronary CT angiography
- Follow-up
- Baseline to 18 months
Methodological detailsplacebo-controlled, double-blind
- Placebo-controlled
- Double-blind
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics. Am Heart J. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →